VCAR33

Anti-CD33 CAR T cell therapy · Vor Biopharma

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VCAR33, covering 2025-07-29 to 2025-07-29. Get the full timeline:

Most recent: Clinical Trial Update: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant [Phase 1, Phase 2]

See pricing